Company: Heidelberg Pharma
Job title: Vice President - Scientific Affairs
Dr George Badescu is Vice President Scientific Affairs at Heidelberg Pharma and has over 15 years of experience in the biotechnology sector. He most recently served as Vice President Scientific Affairs at Abzena Plc where he led the scientific promotion and commercialization of Abzena’s Technologies and Chemistry Research and Manufacturing Services. Prior to this, he led PolyTherics’ Antibody Drug Conjugates (ADCs) program since its inception and is co-inventor on several patents in the field of bioconjugation and ADCs. Prior to this, George has worked on lead identification by viral display technologies, antibody engineering and characterisation of antibody-hapten interactions. George received his PhD from the University of Warwick.
Antibody Targeted Amanitin Conjugates (ATACs) 10:10 am
Evaluate Antigen-Targeted Amanitin-Conjugates (ATACs); A new class of ADCs using the payload Amanitin This payload introduces a novel mode of action into oncology therapy, the inhibition of RNA polymerase II Learn more about this technology platform that includes Amanitin supply, sitespecific conjugation, demonstrated safety profile and biomarker HDP-101 is the first ATAC directed against BCMA…Read more
day: Day Two